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ing microvascular dysfunction (spasm and vasoplegia),1
increased endothelial permeability (edema),2 cardiac
arrhythmias, and myocardial contractile dysfunction.3
Protein phosphorylation by kinases is critical in the
regulation of enzymes and other cellular proteins. The
44-kDa extracellular regulated kinase (ERK1, p44
mitogen-activated protein [MAP] kinase) and its 42-
kDa isoform, ERK2 (p42 MAP kinase), have been
determined to be involved in muscular contraction,4,5
vascular tone,6 and myocardium survival and func-
tion.7 In addition, inhibition of MEK1/2 (mitogen-
activated protein kinase kinase [MAPK kinase]), the
kinase that phosphorylates ERK1/2, reduces edema
induced by tetradecanoyl phorbol acetate in mice,8
pointing to a direct involvement of the MEK/ERK1/2
pathway with acute inflammation. ERK1/2 is activat-
ed by many different stimuli, contributing to cellular
C ardiopulmonary bypass (CPB) is an essential com-ponent of many cardiac operations. There is, how-
ever, significant morbidity associated with CPB includ-
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proliferation and differentiation and cell cycle regu-
lation and survival9 (Fig 1).
Deactivation of ERK1/2 can be mediated by MKP-
1/CL100, a dual specific phosphatase10 that dephos-
phorylates both serine and threonine residues (Fig 1).
MKP-1 (MAP kinase phosphatase), a 39-kDa protein,
is localized in the nucleus and can be rapidly induced
by factors such as oxidative stress.11,12 It remains to be
investigated whether MKP-1 is involved in the patho-
physiologic mechanisms associated with CPB.
More recently, Akt (protein kinase B) (Fig 1), a 57-
kDa protein serine/threonine kinase,13-15 has been
shown to improve survival of cardiomyocytes in cul-
ture deprived of serum, as well as to protect murine
hearts against ischemia/reperfusion injuries in vivo.16
Thus, Akt could possibly play a role in myocardial
protection during CPB. It has also been demonstrated
in vivo that activation of Akt is associated with
vasodilatation through a nitric oxide–dependent
mechanism,17 suggesting that Akt could regulate the
edema that follows CPB.
Activation of ERK1/2 may be dependent on another
enzyme, c-Src, a tyrosine kinase (Fig 1). For example,
c-Src plays a pivotal role in ERK1/2 activation by
hydrogen peroxide in cultured cardiomyocytes.18
Furthermore, a c-Src inhibitor decreases Akt activity
stimulated by ischemia/reperfusion in cultures of car-
diomyocytes,19 pointing to a possible role of c-Src in
post-CPB injury.
Given that the aforementioned signal transduction
pathways are related to cardiac function and edema for-
mation, we studied the protein levels and activity of
selected enzymes in the pathway (Fig 1) in ventricular
and atrial myocardium from pigs before and after CPB.
Using specific antibodies against the phosphorylated
forms of Akt, ERK1/2, MEK1/2, activated c-Src, and
MKP-1, we examined the state of their activation and
protein steady state levels in myocardial tissue.
Material and methods
Animal preparation. Yorkshire pigs (20-25 kg) of either
sex were premedicated with ketamine (10 mg/kg, intramus-
cularly) and anesthetized with α-chloralose and urethane (60
mg/kg and 300 mg/kg intravenously initially and then 15
mg/kg and 60 mg/kg every 60 minutes as needed, respective-
ly). Pigs were intubated and mechanically ventilated
(Harvard Apparatus, Inc, S Natick, Mass). After the induction
of anesthesia and tracheal intubation, a fluid-filled catheter
was introduced into the femoral artery for the measurement
of peripheral arterial pressure. After a sternotomy was per-
formed, pigs were given heparin (500 U/kg) and cannulated
via the distal ascending aorta and the right atrium through the
purse-string sutures. Normothermic CPB was instituted with
an oxygenator (Bentley, Bio-2; Baxter Healthcare Corp,
Irvine, Calif) and standard roller pump. Hemodynamic pa-
rameters were maintained as described in detail previously.20
In brief, blood flow was maintained from 2.0 to 3.0 L · min–1
(2.6-4.2 L · min–1 · m–2) to assure a mean pressure of 40 to 70
mm Hg. Arterial blood gases were adjusted by ventilatory
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Fig 1. Simplified MEK/ERK pathway and its possible relation to c-Src and Akt (see text for details). ERK,
Extracellular regulated kinase; MEK, mitogen-activated protein kinase kinase [MAPK kinase]; MKP-1, mitogen-
activated protein kinase phosphatase; Akt, protein kinase B; c-Src, cellular tyrosine kinase pp60; PI3k, phos-
phatidylinositol 3-kinase.
rate and tidal volume to maintain PO2 more than 80 mm Hg,
PCO2 more than 30 and less than 45 mm Hg, and pH between
7.30 and 7.45. After pigs were weaned from CPB, the mean
post-CPB perfusion pressure was maintained between 40 and
70 mm Hg. Atrial (n = 7) and ventricular (n = 5) tissue sam-
ples were harvested before institution of 90 minutes of CPB
and after 90 minutes of post-CPB perfusion. In control ani-
mals (n = 4), the same surgical procedure described above
was used, except that after sternotomy, catheter placement,
and heparinization, CPB was not instituted. Samples of atrial
and ventricular myocardium were harvested after catheter
placement (equivalent to before CPB), after 90 minutes, and
at the end of 180 minutes (equivalent to after 90 minutes of
post-CPB perfusion).
All animals received humane care in compliance with the
Beth Israel Deaconess Medical Center Animal Care and Use
Committee and the National Research Council’s “Guide for
the Care and Use of Laboratory Animals,” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press,
revised 1996.
Immunoblotting. Total lysate from atrial and ventricular
tissue was obtained by homogenization (PowerGen 125
Homogenizer; Fischer, Pittsburg, Pa) for 30 seconds on ice in
lysis buffer containing 1% NP-40 surfactant, 0.5% sodium
deoxycholate, and 0.1% sodium dodecyl sulfate (SDS) and
by centrifugation at 12,000g for 10 minutes at 4°C to separate
solubilized from unsolubilized protein. The supernatant pro-
tein concentration was measured spectrophotometrically at a
595-nm wave length (DU640; Beckman Coulter, Inc,
Fullerton, Calif) using a BCA protein assay kit (Pierce
Chemical Company, Rockford, Ill). Total protein was frac-
tionated on 10% SDS-polyacrylamide gel electrophresis and
transferred to a polyvinylidene difluoride membrane
(Immobilon-P; Millipore Corporation, Bedford, Mass) using
a semi-dry transfer apparatus (Millipore). Membranes were
stained with Ponseau S,21 digitized (see below), and then
incubated with 5% nonfat dry milk in 50 mmol/L Tris-HCl,
pH 8.0, 100 mmol/L NaCl, and 0.1% Tween 20 (TBST)
buffer for 1 hour at room temperature to block nonspecific
binding. Membranes were incubated with rabbit anti-phos-
pho p44/42 MAPK (New England Biolabs, Beverly, Mass)
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Fig 2. Anti-phospho-ERK1/2 (A), anti-phospho-MEK1/2 (B), anti-MKP-1 (C), and respective control (D, E, and
F) immunoblottings of total protein lysate from pig ventricle before (b) and 90 minutes after (a) post-CPB perfu-
sion or 180 minutes after start of sham operations in controls as described in “Material and methods.” ERK1/2
phosphorylation significantly decreases after 90 minutes of CPB and 90 minutes of post-CPB perfusion (0.39-fold
± 0.15 as compared with basal levels, P = .006, n = 5), as well as MEK1/2 phosphorylation (0.36-fold ± 0.22 as
compared with basal levels, P = .009, n = 5), whereas MKP-1 levels increase perfusion (5.11-fold ± 2.2 as com-
pared with basal levels, P = .03, n = 5). No significant changes are observed in controls. The figure shows the result
of 2 different experiments representative of 5 pigs studied (CPB) or 1 experiment representative of 4 controls.
Ponseau S or total protein was used to ascertain proper protein fractionation and transfer.
1:2500 (v/v) dilution in 2.5% nonfat dry milk, rabbit anti
p44/42 MAPK (New England Biolabs) 1:2500 (v/v) dilution,
rabbit anti-phospho MEK1/2 (New England Biolabs) 1:1000
(v/v) dilution, mouse anti-MEK-1 (Zymed Laboratories, San
Francisco, Calif) 1:1000 (v/v) dilution, rabbit anti-phospho-
Akt (New England Biolabs) 1:1000 (v/v) dilution, goat anti-
MKP-1 (V-15) (Santa Cruz Biotechnology, Santa Cruz, Calif)
1:1000 (v/v) dilution, rabbit anti-c-Src (kindly provided by
Dr Joan Brugges), and activated mouse anti-c-Src22 (gener-
ously provided by Dr Kawakatsu) 1/1000 (v/v) for 2 hours for
immunoblotting. After being washed with TBST, the mem-
branes were incubated for 1 hour in 2.5% nonfat dry milk in
TBST containing 1:3000 diluted with the appropriated sec-
ondary antibody either a sheep anti-mouse (Amersham
Pharmacia Biotech Inc, Piscataway, NJ), rabbit anti-goat
immunoglobulin G, or sheep anti-rabbit immunoglobulin G
(Jackson Immunolabs, West Grove, Pa), at 1:5000 (v/v) dilu-
tion conjugated to horseradish peroxidase. Peroxidase activi-
ty was visualized by means of an enhanced chemilumines-
cence substrate system as previously described23 and exposed
to x-ray films (Amersham, Arlington Heights, Ill).
Confocal microscopy. Frozen tissue samples were sectioned
(5 µm thickness) in a cryostat (Tissue Tek; Miles Laboratories,
Elkhart, Ind) and fixed for 20 minutes in 4% (w/v)
paraformaldehyde solution in phosphate-buffered saline solu-
tion (PBS), followed by permeabilization with 1% (w/v) SDS in
PBS for 5 minutes.24 After being washed with PBS, sections
were blocked overnight at 4°C with 1.5% bovine serum albu-
min against nonspecific binding. Different sections from the
same tissues were then incubated for 1 hour at room tempera-
ture with rabbit anti-phospho p44/42 MAPK (New England
Biolabs) 1:100 (v/v) dilution in 1.5% (w/v) bovine serum albu-
min in PBS, rabbit anti-phospho MEK1/2 (New England
Biolabs) 1:100 (v/v) dilution, or goat anti-MKP-1 (V-15) (Santa
Cruz Biotechnology) 1:100 (v/v) dilution. The sections were
washed 4 times in PBS and incubated for 30 minutes in 1.5%
bovine serum albumin in PBS containing a 1:300 dilution of the
appropriated secondary antibody, a sheep anti-mouse (Sigma
Chemical Co, St Louis, Mo), donkey anti-goat immunoglobulin
G (Jackson Immunolabs), or sheep anti-mouse immunoglobu-
lin G (Jackson Immunolabs), all conjugated with Cy3. The
slides were then mounted with Vectashield (Vector
Laboratories, Inc, Burlingame, Calif) and observed on a Bio-
Rad MRC-1024ES confocal microscope (Bio-Rad
Microscience, Hercules, Calif).
Data acquisition and statistical analysis. Immunoblottings
were analyzed after digitalization of x-ray films using a flat-bed
scanner (ScanJet 4c; Hewlett-Packard Company, Palo Alto,
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Fig 3. Anti-phospho-ERK1/2 (A), anti-phospho-MEK1/2 (B), anti-MKP-1 (C), and respective control (D, E, and
F) immunoblottings of total protein lysate from pig atria before (b) and 90 minutes after (a) post-CPB perfusion or
180 minutes after start of sham operations in controls as described in “Material and methods.” ERK1/2 phospho-
rylation significantly decreases after 90 minutes of CPB and 90 minutes of post-CPB perfusion tissue (0.47-fold ±
0.10 as compared with basal levels, P = .007, n = 7), as well as MEK1/2 phosphorylation (0.49-fold ± 0.03 as com-
pared with basal levels, P = .008, n = 7), whereas MKP-1 levels increased (4.35-fold ± 1.15 as compared with basal
levels, P = .02, n = 4). The figure shows the result of 2 different experiments representative of 7 pigs studied (CPB)
or 1 experiment representative of 4 controls. Ponseau S or total protein was used to ascertain proper protein frac-
tionation and transfer.
Calif) and NIH Image 1.62 software (National Institutes of
Health, Bethesda, Md). Comparisons between samples were
analyzed by 1-way analysis of variance followed by a 2-tailed t
test using Microsoft Excel software (Microsoft Corporation,
Seattle, Wash). Values are expressed as mean fold change ±
standard deviation of the mean. Ponseau S staining was used to
determine proper protein fractionation and equivalent loading.
Only samples with similar protein fractionation and protein
loading less than 20% differences were analyzed further. The
optical density ratio of the bands to that of Ponseau S was used
to correct for small uneven loading (<20%).
Results
Phosphorylation levels of ERK1/2 decrease after
CPB. The presence of an in vivo phosphorylation of
ERK1/2 in basal levels was observed in both ventricu-
lar (Fig 2, A and D) and atrial (Fig 3, A and D)
myocardium. Whereas levels of phosphorylated
ERK1/2 decreased in ventricular myocardium (0.39-
fold ± 0.15 as compared with basal levels, P = .006,
n = 5) after 90 minutes of post-CPB perfusion (Fig 2,
A), levels did not decrease (1.07-fold ± 0.18 as com-
pared with basal levels, P > .2, n = 4) after 180 minutes
in controls (Fig 2, D).
A similar picture was observed in atrial myocardi-
um. After 90 minutes of post-CPB perfusion, a
decrease in phosphorylated levels of ERK1/2 in atrial
tissue (0.47-fold ± 0.10 as compared with basal lev-
els, P = .007, n = 7) was consistently observed, as
shown in Fig 3, A. However, protein levels of ERK1/2
were not modified after 90 minutes of post-CPB per-
fusion (0.96-fold ± 0.01 as compared with basal lev-
els, P = .06, n = 7). In controls (Fig 3, D), both phos-
phorylated (1.12-fold ± 0.28 as compared with basal
levels, P = .15, n = 4) and total ERK1/2 (1.02-fold ±
0.09 as compared with basal levels, P > .2, n = 4) lev-
els did not significantly change after 180 minutes of
sham operations not involving CPB.
Phosphorylation of MEK1/2 correlates with phos-
phorylation of ERK1/2. Since the steady state of
ERK1/2 phosphorylation is altered after CPB, it is pos-
sible that similar changes would be observed in the
phosphorylation steady state of MEK1/2, the upstream
kinases that phosphorylate ERK1/2. As illustrated in
Fig 2, B, phosphorylated levels of MEK1/2 significant-
ly decreased in ventricular tissue (0.36-fold ± 0.22 as
compared with basal levels, P = .009, n = 5) after 90
minutes of CPB perfusion. However, they did not
decrease (1.07-fold ± 0.18 as compared with basal lev-
els, P = .10, n = 4) after a total of 180 minutes in con-
trols (Fig 2, E). Such findings correlate well with
ERK1/2 dephosphorylation.
As observed in ventricular myocardium, there was a
prominent dephosphorylation of MEK1/2 in atrial
myocardium (0.49-fold ± 0.03 as compared with basal
levels, P = .008, n = 7) (Fig 3, B) without significant
changes in MEK1/2 protein levels (0.96-fold ± 0.01 as
compared with basal levels, P > .2, n = 7). In controls
(Fig 3, E), neither phosphorylated MEK1/2 levels (1.12-
fold ± 0.28 as compared with basal levels, P > .2, n = 4)
nor total MEK-1 levels (1.08-fold ± 0.1 as compared
with basal levels, P > .2, n = 4) were significantly
changed after 180 minutes of sham operations not
involving CPB.
Induction of MKP-1 expression after CPB. A
robust induction of MKP-1 immunoreactivity was
observed in ventricular myocardium after 90 minutes
of CPB and 90 minutes of post-CPB perfusion (5.11-
fold ± 2.2 as compared with basal levels, P = .03,
n = 5), as shown in Fig 2, C. At the same time point in
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Fig 4. Immunoblotting of total protein lysate from pig atria before (b) and 90 minutes after (a) post-CPB perfusion
as described in “Material and methods.” A, The lane with total c-Src was probed with a c-Src antibody 327. The
lane with activated c-Src was probed with antibody that only recognizes c-Src in its active form (antibody 29). B,
Akt phosphorylation was not significantly different between before and after post-CPB perfusion. The figure shows
the results of 1 or 2 different experiments representative of 6 pigs studied. Ponseau S was used to ascertain proper
protein fractionation and transfer.
controls (Fig 2, F), however, MKP-1 was not induced
(1.07-fold ± 0.13 as compared with basal levels,
P = .11, n = 4). It is interesting to note that MKP-1 can
be detectable in samples before CPB, indicating basal
expression in porcine myocardium.
Conspicuous induction of MKP-1 was also observed
in atrial tissue 90 minutes after initiation of post-CPB
perfusion (Fig 3, C) (4.35-fold ± 1.15 as compared with
basal levels, P = .02, n = 4). In controls, however,
MKP-1 expression (Fig 3, F) was not significantly
altered (1.13-fold ± 0.35 as compared with basal levels,
P = .08, n = 4).
Active forms of c-Src and phospho-Akt did not
change after CPB. In the same atrial tissues as ana-
lyzed above, neither c-Src protein levels (1.01-fold ±
0.01 as compared with basal levels, P = .09, n = 6) nor
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Fig 5. A, Confocal microscopy images from pig atria before (left) and 90 minutes after (right) post-CPB perfusion as
described in “Material and methods.” Notice the intensity decrease of phospho-ERK1/2 signal post-CPB perfusion,
confirming immunoblotting observations. Images were obtained from similar fields and same magnification and
image adjustments. B, Confocal microscopy images from pig atria before (left) and 90 minutes after (right) post-CPB
perfusion as described in “Material and methods.” MKP-1 is induced at the end of post-CPB perfusion, localizing
mainly in cardiomyocyte nuclei. Images were obtained from similar fields, magnifications, and adjustments.
A
B
c-Src activity (0.99-fold ± 0.05 as compared with basal
levels, P > .2, n = 6) were modified (Fig 4, A). Similar
results were obtained for activity of Akt (0.98-fold ±
0.1 as compared with basal levels, P = .17, n = 7) and
Akt protein levels (0.96-fold ± 0.01 as compared with
basal levels, P > .2, n = 7) (Fig 4, B).
In ventricular myocardium, Akt results were similar
to those observed in atrial tissue. After 90 minutes of
post-CPB perfusion (0.92-fold ± 0.14 as compared
with basal levels, P > .2, n = 5) and in control pigs
(1.02-fold ± 0.07 as compared with basal levels, P >
.2, n = 4), significant changes were not observed (data
not shown).
Confocal microscopy of atrial tissue corroborate
immunoblotting results. The decrease of ERK1/2
phosphorylation after 90 minutes of CPB and 90 min-
utes of post-CPB perfusion was also observed by con-
focal microscopy (Fig 5, A). Despite the difference in
intensity, the phosphorylated form of ERK1/2 localized
to the cardiomyocyte surfaces and nuclei before CPB
and after 90 minutes of post-CPB perfusion.
Phosphorylated MEK1/2 was mainly observed in
cardiomyocyte nuclei, with discrete cytoplasmic stain-
ing. Phosphorylated MEK1/2 was slightly decreased
90 minutes after CPB termination (data not shown).
MKP-1 immunostaining, almost exclusively ob-
served on cardiomyocyte nuclei (Fig 5, B), confirmed
the evident induction of expression of this dual phos-
phatase. Despite similar distribution at both time
points, a more intense staining was observed after 90
minutes of post-CPB perfusion, and this correlated
with immunoblotting results.
Discussion
The main findings of this study are that the levels of
phosphorylated ERK1/2 were consistently lower than
baseline after 90 minutes of normothermic CPB and 90
minutes of post-CPB perfusion. These decreases were
accompanied by a decrease in MEK1/2 phosphoryla-
tion, indicating a decrease in upstream activation.
MKP-1 protein levels were considerably increased,
adding a downstream component to ERK1/2 inactiva-
tion. Because we were unable to detect any significant
change in c-Src activity or phospho-Akt after CPB, a
certain level of specificity to the MEK/ERK pathway is
revealed. These results collectively point to a general
decrease in the MEK/ERK signal transduction module
after CPB.
The mechanisms regulating signal transduction have
been studied mainly in cell culture models. Since cell
cultures are kept “quiescent” before experimentation,
inactivation of signal transduction from a basal level is
frequently overlooked. In vivo, however, it appears that
signal transduction pathways have a high basal level of
activity. It is important to consider, as shown by
immunoblotting and immunostaining, that basal levels
of phosphorylated (active) ERK1/2 and MEK1/2, as
well as MKP-1 expression, are detected in pig hearts.
Because atrial and ventricular myocardium respond
similarly to CPB, it is suggested that atrial sampling (a
more convenient approach in patients) may well reflect
the changes occurring in ventricular myocardium.
It is interesting to note that the MEK/ERK pathway
is inactivated by CPB. In fact, different models of
ischemia/reperfusion using either cardiomyocyte cul-
tures7 or isolated hearts25-28 showed that ERK1/2 is
activated after reperfusion. However, ERK1/2 phos-
phorylation shows a characteristic trend in these stud-
ies: rapid induction after initiation of reperfusion,
reaching a peak and decreasing at the end of the reper-
fusion period. Consequently, it cannot be ruled out that
during the 90 minutes of CPB and 90 minutes of post-
CPB perfusion, variations in the activity did not occur,
nor can it be assumed that different results would not
be obtained at later time points. Because in our proto-
col we harvested the samples after 90 minutes of post-
CPB perfusion, it is possible that ERK1/2 activation
might have occurred before we collected our samples.
In relation to our findings, it has been reported29 that
ERK1/2 phosphorylation in human atrial tissue
increases during cardioplegia; ERK1/2 activity was
higher after ischemia and showed a further increase
after reperfusion. The difference could be related to the
fact that the present study does not use an ischemia/
reperfusion model, because cardioplegia was not used.
In addition, in 6 of 8 patients from the study by Talmor
and colleagues,29 the surgical procedure was shorter
than our experimental design (ischemia, 44.3 ± 7.7
minutes; reperfusion, 36.3 ± 15.7), an important issue
considering the possibility that the activation might not
be sustained during the postoperative period.
Our data reveal not only that CPB induced the
expression of MKP-1 in the heart, but also that MKP-1
expression is localized to the nuclei of the cardiomy-
ocytes. This was not surprising considering that
ERK1/2 dephosphorylation can be mediated by MKP-
1.10 For instance, angiotensin II, an activator of
ERK1/2 in smooth muscle cells,30 induces MKP-1 pro-
tein synthesis within 1 hour of stimulation. More
important, when protein synthesis is blocked and
MKP-1 expression is inhibited, ERK1/2-stimulated
phosphorylation is not reversed.31 Nevertheless, MKP-
1 cannot be solely responsible for ERK1/2 dephospho-
rylation in our CPB model, because MEK1/2 dephos-
phorylation clearly points to the involvement of
upstream signals. Thus, CPB is likely to generate dif-
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ferent levels of ERK inactivation, one from upstream
signals (MEK) and the other from parallel, inhibitory
molecules (MKP-1).
To which degree the changes observed in the present
study relate to the well-established morbidity associat-
ed with CPB is not clear at this time. However, our
studies support an inactivation of MEK/ERK pathways
that could contribute to myocardial depression
observed after CPB. In fact, in vitro32 and ex vivo5
studies have revealed that PD98059, a MEK1/2 chemi-
cal inhibitor, prevented the increase in muscular con-
traction–induced ERK1/2 phosphorylation. Also, in rat
aorta vascular smooth muscle cells subjected to
mechanical stretch, ERK1/2 was phosphorylated to a
peak of activity at 20 minutes, returning to basal levels
after 30 minutes of stimulation.33 These observations
suggest that, in our model, a certain degree of car-
diomyocyte contraction dysfunction can be either a
cause or effect of ERK1/2 dephosphorylation. Also,
ERK1/2 inactivation can be a cause of the systemic and
coronary vascular relaxation observed after CPB.
Another point to be considered is the role of ERK1/2
in preconditioning. In preconditioning, where the heart
is subjected to short periods of ischemia and reperfu-
sion before a sustained ischemia/reperfusion period,34
ERK activity increases up to 89% and translocates to
the nucleus.35 Given that in our study ERK1/2 is
dephosphorylated, it is likely that the hearts of the pigs
subjected to CPB lacked the presumptive protective
effect of preconditioning. Indeed, a recent pig model
study shows that specific MEK1/2 inhibitors reduce
ERK activity and may block the beneficial effects of
preconditioning.36 This suggests that the inactivation of
ERK during CPB may contribute to myocardial injury.
In vitro studies show that the addition of MEK1/2
inhibitor PD98059 to cardiomyocytes subjected to
ischemia for 2 hours, followed by reoxygenation for
24 hours, induced apoptosis while inhibiting ERK
phosphorylation completely.7 Consequently, the rela-
tionship between ERK dephosphorylation (also
demonstrated in our data) and cardiomyocyte apopto-
sis may be clinically relevant in CPB. Likewise, the
induction of MKP-1 that was observed after post-CPB
perfusion should be considered detrimental to car-
diomyocyte survival.
There is also ex vivo evidence that decreased ERK1/2
activity may be an important feature in cardiac dysfunc-
tion, because MEK1/2 inhibition (by pretreatment with
PD98059) in isolated rat hearts subjected to ischemia
and reperfusion reduced ERK activation by 71% and
aggravated cardiac function injury.7 Thus, it appears that
the ERK1/2 dephosphorylation in the myocardium after
post-CPB perfusion may have clinical significance with
regard to preservation of cardiac function.
In conclusion, the MEK/ERK pathway is partially
inactivated after 90 minutes of normothermic CPB fol-
lowed by 90 minutes of post-CPB reperfusion in pigs.
Further experiments need to determine the exact time
course of ERK/MEK inactivation, as well as the role of
the MEK/ERK pathway, in causing detrimental effects in
the myocardium and the coronary and peripheral vascu-
lature.
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